Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Epsilogen Ltd.
Headquarters: London, United Kingdom
Website: https://epsilogen.com/
Year Founded: 2016
Status: Private
BioCentury | Sep 12, 2024
Finance
Venture Report: Big rounds for Candid, Superluminal, PanTera
Plus: Rounds for Radiant, Vironexis, Bambusa, OrsoBio and F2G
BioCentury | May 2, 2024
Management Tracks
McDonnell now CEO of Agilent
Plus: Dubensky to lead ImmuneSensor and updates from NORD and Epsilogen
BioCentury | Nov 15, 2023
Management Tracks
CFO Fox moving on from Nuvation
Plus: Nucleome hires Harrison as CSO, and updates from Senisca, HaemaLogiX and Tevard
BioCentury | Apr 27, 2023
Management Tracks
BMS’s Caforio to retire as CEO
Plus: Rectify hires Minegishi and updates from Epsilogen, Novo and more
BioCentury | Apr 27, 2022
Data Byte
Europe’s biggest biotech venture rounds so far this year
Eight European therapeutics developers have raised venture rounds of at least $50M year-to-date
BioCentury | Mar 3, 2022
Deals
March 2 Quick Takes: Sanofi adds mAb masking tech in Adagene deal
Plus NIH ends only active arm in ACTIV-2 and updates from Oculis, Ampio, Inovio, Epsilogen, Lexeo, BlueWillow-Medigen, Epigeneron
BioCentury | Oct 28, 2020
Product Development
Data Byte: FOLR1 pipeline for cancer
At least four antibody-drug conjugates, one antibody and two vaccines targeting FOLR1 are in development to treat cancer. The lead program is in Phase III testing for ovarian cancer.
BioCentury | Jun 5, 2020
Emerging Company Profile
Epsilogen: co-opting IgE antibodies against cancer
Epsilogen leverages natural high affinity of IgE for immune cells to target solid tumors
Items per page:
1 - 9 of 9